Compare Stocks → Wall Street Legend Issues New NVDA Warning (From Chaikin Analytics) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CWBROTCMKTS:IGXTNASDAQ:MNPRNASDAQ:VCNXNASDAQ:VYNE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCWBRCohBar$0.80-11.1%$0.82$0.51▼$6.90$2.33M1.541,006 shs358 shsIGXTIntelGenx Technologies$0.15-6.3%$0.16$0.09▼$0.22$26.20M2.43101,811 shs81,018 shsMNPRMonopar Therapeutics$0.64-2.6%$0.75$0.27▼$1.75$11.17M1.194.28 million shs14,984 shsVCNXVaccinex$5.40+7.8%$7.55$4.43▼$100.80$6.64M0.7411,464 shs3,436 shsVYNEVYNE Therapeutics$2.70+5.1%$2.44$1.67▼$8.73$38.07M1.23120,568 shs51,403 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCWBRCohBar-11.15%-11.14%+5.24%+1.23%-54.29%IGXTIntelGenx Technologies-8.48%-6.25%-11.00%+6.16%-18.48%MNPRMonopar Therapeutics+1.08%+1.08%-7.46%+77.57%-40.81%VCNXVaccinex+0.91%+3.41%-35.46%-39.43%-93.80%VYNEVYNE Therapeutics+10.78%+7.08%+4.05%+44.38%-42.51%Wall Street Legend Issues New NVDA Warning (Ad)Legendary Stockpicker: "Buy this A.I. stock NOW" His award-winning system pinpointed NVDA and META before both stocks doubled. Now it's flashing "BUY" on this under-the-radar A.I. stock.Click here for the stock detailsMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics2.4146 of 5 stars3.55.00.00.00.61.70.6VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AVYNEVYNE Therapeutics1.9476 of 5 stars3.53.00.00.00.01.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCWBRCohBarN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AMNPRMonopar Therapeutics3.00Buy$2.00212.50% UpsideVCNXVaccinexN/AN/AN/AN/AVYNEVYNE Therapeutics3.00Buy$7.38173.15% UpsideCurrent Analyst RatingsLatest IGXT, VYNE, VCNX, CWBR, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.002/29/2024VYNEVYNE TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.75(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AIGXTIntelGenx Technologies$1.04M25.19N/AN/A($0.07) per share-2.14MNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/AVCNXVaccinex$570K11.65N/AN/A($2.59) per share-2.08VYNEVYNE Therapeutics$420K90.64N/AN/A$6.36 per share0.42Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCWBRCohBar-$12.18M-$4.36N/A∞N/AN/AN/AN/A5/13/2024 (Estimated)IGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-955.44%N/A-128.18%N/AMNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)VCNXVaccinex-$20.25M-$100.86N/A∞N/AN/A-2,667.31%-571.70%5/20/2024 (Estimated)VYNEVYNE Therapeutics-$28.45M-$7.04N/AN/AN/A-6,710.38%-77.46%-62.93%5/9/2024 (Estimated)Latest IGXT, VYNE, VCNX, CWBR, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/2/2024Q4 2023VCNXVaccinexN/A-$39.40-$39.40-$39.40N/AN/A3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/A3/21/2024Q4 2023IGXTIntelGenx TechnologiesN/A-$0.02-$0.02-$0.03N/A$0.43 million 2/29/2024Q4 2023VYNEVYNE Therapeutics-$0.50-$0.20+$0.30-$0.20$0.15 million$0.08 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCWBRCohBarN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/AVYNEVYNE TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCWBRCohBarN/AN/AN/AIGXTIntelGenx TechnologiesN/A0.410.40MNPRMonopar TherapeuticsN/A4.174.17VCNXVaccinexN/A0.570.57VYNEVYNE TherapeuticsN/A12.7312.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCWBRCohBar2.47%IGXTIntelGenx TechnologiesN/AMNPRMonopar Therapeutics1.83%VCNXVaccinex50.11%VYNEVYNE Therapeutics83.78%Insider OwnershipCompanyInsider OwnershipCWBRCohBar6.51%IGXTIntelGenx Technologies42.05%MNPRMonopar Therapeutics41.60%VCNXVaccinex51.50%VYNEVYNE Therapeutics1.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCWBRCohBar92.91 million2.72 millionNot OptionableIGXTIntelGenx Technologies4174.66 million101.21 millionNot OptionableMNPRMonopar Therapeutics1117.45 million10.19 millionNot OptionableVCNXVaccinex381.23 million598,000No DataVYNEVYNE Therapeutics1014.10 million13.85 millionNot OptionableIGXT, VYNE, VCNX, CWBR, and MNPR HeadlinesSourceHeadlineVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com - April 13 at 8:27 AMAcne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032pharmiweb.com - March 28 at 12:46 PMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferencefinance.yahoo.com - March 19 at 9:08 AMVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conferenceglobenewswire.com - March 19 at 8:00 AMHere's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Nowzacks.com - March 13 at 10:56 AMWhat Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stockzacks.com - March 8 at 1:01 PMWall Street Breakfast Podcast: NYCB Gets $1B Investment Boostseekingalpha.com - March 7 at 8:21 AMVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lagfinance.yahoo.com - March 3 at 8:59 AMBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developmentsmarkets.businessinsider.com - February 29 at 7:00 PMVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updatefinanznachrichten.de - February 29 at 10:04 AMVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Updateglobenewswire.com - February 29 at 8:00 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumfinance.yahoo.com - February 27 at 8:06 AMVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposiumglobenewswire.com - February 27 at 8:00 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 21 at 8:16 AMVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 21 at 8:00 AMFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stockfinance.yahoo.com - February 2 at 7:18 AMBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Resultsmarkets.businessinsider.com - January 10 at 4:27 PMPrurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Studyfmiblog.com - January 4 at 12:32 AMVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directorsfinance.yahoo.com - January 3 at 9:29 AMInvesting in VYNE Therapeutics Inc [VYNE]: What You Must Knowknoxdaily.com - January 1 at 10:15 AMVYNE Therapeutics says director Lepore buys 13K shares in comsn.com - November 20 at 3:25 PMCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Incfinance.yahoo.com - November 14 at 5:53 PMVYNE Therapeutics files to sell 36.27M shares for holdersmsn.com - November 13 at 5:35 PMVYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 13 at 12:34 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCohBarNASDAQ:CWBRCohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.IntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.VYNE TherapeuticsNASDAQ:VYNEVYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.